| Name | (Z)-LFM-A13 |
| Description | (Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK. |
| In vitro | In BTK+ B-lineage leukemic cells, (Z)-LFM-A13 enhances their sensitivity to ceramide- or vincristine-induced apoptosis. [1] In BCL-1 cells, NALM-6 cells, or normal BALB/c splenocytes, LFM-13 inhibits the enzymatic activity of BTK in BCL-1 cells without affecting the BTK protein expression levels [2] In human neutrophils, (Z)-LFM-A13 decreases the tyrosine phosphorylation induced by fMet-Leu-Phe and inhibits the production of superoxide anions and the stimulation of adhesion, chemotaxis, and phospholipase D activity. [3] |
| In vivo | In BALB/c mice bearing BCL-1 leukemia, combination of(Z)-LFM-A13 (50 mg/kg/day i.p.) and the standard triple-drug VPL prolongs the median survival time. [2] In primary myeloma-bearing SCID-rab mice,(Z)-LFM-A13 inhibits osteoclast activity, prevents myeloma-induced bone resorption and suppresss myeloma growth. [4] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 2.5 mg/mL (6.94 mM), Sonication is recommended.
DMSO : 67 mg/mL (186.11 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Polo-like Kinase (PLK) | PLK | LFM-A-13 | LFM-A13 | LFMA13 | LFM A13 | Janus kinase | JAK | Inhibitor | inhibit | BTK | Bruton tyrosine kinase |
| Inhibitors Related | Delgocitinib | Ruxolitinib | Atinvicitinib | Pyridoxine | Tofacitinib Citrate | Resveratrol | Ibrutinib | Remibrutinib | JAK-IN-10 | 2,4,5-Trimethoxybenzoic acid | Lentinan | Raspberry ketone glucoside |
| Related Compound Libraries | Highly Selective Inhibitor Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
United States
